Beyond belief - How people feel about taking medications for heart disease

New England Journal of Medicine

Volumn 372, Issue 2, 2015, Pages 183-187

  Rosenbaum, Lisa ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADVERSE OUTCOME; ARTICLE; AVERSIVE BEHAVIOR; AVOIDANCE BEHAVIOR; DENIAL; DRUG DEPENDENCE; HEART INFARCTION; HUMAN; IDENTITY; LIFESTYLE MODIFICATION; MEDICATION COMPLIANCE; PATIENT EDUCATION; PERCEPTION; RISK BENEFIT ANALYSIS; ATTITUDE TO HEALTH; DRUG THERAPY; EMOTIONAL INTELLIGENCE; HEART DISEASES; PSYCHOLOGY;

DRUG THERAPY; EMOTIONAL INTELLIGENCE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEART DISEASES; HUMANS; MEDICATION ADHERENCE;

EID: 84920584272     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMms1409015     Document Type: Article

References (12)

1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97.
2. Akincigil A, Bowblis JR, Levin C, Jan S, Patel M, Crystal S. Long-term adherence to evidence based secondary prevention therapies after acute myocardial infarction. J Gen Intern Med 2008;23:115-21.
3. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009;119: 3028-35.
4. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, developed in collaboration with the Canadian Cardiovascular Society, endorsed by the American Academy of Family Physicians: 2007 Writing Group to review new evidence and update the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction, writing on behalf of the 2004 Writing Committee. Circulation 2008;117:296-329.
5. Loewenstein GF, Weber EU, Hsee CK, Welch N. Risk as feelings. Psychol Bull 2001;127:267-86.
6. Finucane M, Alhakami A, Slovic P, Johnson S. The affect heuristic in judgments of risks and benefits. J Behav Decis Making 2000;13:1-17.
7. Slovic P, Peters E, Grana J, Berger S, Dieck GS. Risk perception of prescription drugs: results of a national survey. Drug Inform J 2007;41:81-100.
8. Lown B. Social responsibility of physicians (Essay 29) (personal blog) (http://bernardlown.wordpress.com/2012/04/29/social-responsibility-of-physicians).
9. Balady GJ, Ades PA, Bittner VA, et al. Referral, enrollment, and delivery of cardiac rehabilitation/secondary prevention programs at clinical centers and beyond: a presidential advisory from the American Heart Association. Circulation 2011;124: 2951-60.
10. Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med 2011;365:2088-97.
11. McAfee T, Davis KC, Alexander RL Jr, Pechacek TF, Bunnell R. Effect of the first federally funded US antismoking national media campaign. Lancet 2013;382:2003-11.
12. Tilson HH. Adherence or compliance? Changes in terminology. Ann Pharmacother 2004;38:161-2.